HAS opinions and decisions
La fiche de bon usage du médicament intitulée « Xolair (omalizumab) dans le traitement de l’asthme sévère», ci-jointe, est adoptée.
See also
HAS opinions and decisions
17/11/2017
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
CzEE7kp4cayREpmS